Drug Trial Radar · NCT07079228
A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer
Last checked: Nov 19, 2026Latest source record: Sep 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
602
Planned (sponsor's estimate)
Start
Sep 8, 2025
Primary completion
Dec 2028
Study completion Sep 2030
Sponsor
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to evaluate the efficacy of QLS31905 in combination with chemotherapy (nab-paclitaxel plus gemcitabine \[AG\]) versus placebo in combination with chemotherapy (AG) in the treatment of CLDN18.2-positive advanced pancreatic cancer in adult participants.
Conditions
- Pancreatic Cancer
Interventions
QLS31905Drug
QLS31905 will be administered as an IV infusion.
Nab-paclitaxel.Drug
Nab-paclitaxel will be administered as an IV infusion.
GemcitabineDrug
Gemcitabine will be administered as an IV infusion.
Placebo for QLS31905Drug
Placebo will be administered as an IV infusion.
Nab-paclitaxel.Drug
Nab-paclitaxel will be administered as an IV infusion
GemcitabineDrug
Gemcitabine will be administered as an IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Suryival(OS)Time frame: Up to 48 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.